How can the UK remain attractive to the pharmaceutical industry? Lords to ask Amercian pharmaceutical group and academic experts
The House of Lords Science and Technology Committee will continue taking evidence for its inquiry into Life Sciences and the Industrial Strategy on Tuesday 28 November. The Committee will question academics and representatives of the American Pharmaceutical Group.
This week, the Committee will hear the views of the US pharmaceutical industry on why some pharmaceutical companies have moved out of the UK in recent years and question leading academics on why it is difficult for the UK to match the success of the US in the life sciences sector.
The first evidence session will begin at 10.10 am and the Committee will question:
- Dr Michael Hopkins, Senior Lecturer, Science Policy Research Unit, University of Sussex
- Professor Andy Westwood, Member of the Industrial Strategy Commission, and Professor of Government Practice and Vice Dean of Humanities at the University of Manchester
The second evidence session will begin at 11:00am:
- Erik Nordkamp, Chair of the American Pharmaceutical Group and UK Managing Director, Pfizer
- Mark Hicken, Vice Chair of the American Pharmaceutical Group and UK Managing Director, Janssen
- Louise Houson, UK Managing Director, MSD
Questions the witnesses are likely to face include:
- How likely is it that the UK can meet the goal of four companies in life sciences with market capitalisation of £20bn in the next 10 years?
- What impact is the relocation of the European Medicines Agency from London likely to have?
- How would you describe the current relationship between the NHS and industry?
The evidence session will begin at 10.10 am on Tuesday 28 November in Committee Room 4A of the House of Lords.
